Stocks of recombinant, replication-deficient adenovirus free of

Details Stocks of recombinant, replication-deficient adenovirus free of Stocks of recombinant, replication-deficient adenovirus free of

1996-11-26

1999-11-30

Priebe, Scott D.

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Preparing compound containing saccharide radical

4353201, 435325, 435366, 435456, C12N 510, C12N 1564, C12N 1586

Patent

active

059941065

ABSTRACT:
The present invention provides multiply deficient adenoviral vectors and complementing cell lines. Also provided are recombinants of the multiply deficient adenoviral vectors and a therapeutic method, particularly relating to gene therapy, vaccination, and the like, involving the use of such recombinants.

REFERENCES:
patent: 4405712 (1983-09-01), Vande Woude
patent: 4497796 (1985-02-01), Salser et al.
patent: 4727028 (1988-02-01), Santerre et al.
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 5190931 (1993-03-01), Inouye
patent: 5208149 (1993-05-01), Inouye
patent: 5518913 (1996-05-01), Massie et al.
Armentano et al., Human Gene Therapy, 6, 1343-1353 (1995).
Berkner, BioTechniques, 6, 616-629 (1988).
Gilardi et al., FEBS, 267, 60-62 (1990).
Imler et al., Gene Therapy, 3, 75-84 (1996).
Mittereder et al., Human Gene Therapy, 5, 771-729 (1994).
Morin et al., Molecular and Cellular Biology, 4372-4380 (Oct. 1989).
Simon et al., Human Gene Therapy, 4, 771-780 (1993).
Yang et al., Nature Genetics, 7, 362-369 (1994).
T. Friedmann et al. Scientific American pp. 96-101, Jun. 1997.
S. Orkin et al. NIH Report on Gene Therapy, Dec. 1995.
R. Crystal Nature Medicine 1 (1) 15-17, 1995.
R. DeMatteo et al. Transplantation 63(2):315-9, 1997.
A. Schulick et al. J. Clin. Invest. 99(2) 209-19, 1997.
Q. Wang et al. Nature Medicine 2(6) 714-6, 1996.
Declaration of I. Koveschi, filed May 13, 1996 in 08/258,416, 1996.
D. Davidson et al. J. Virology 61(4) 1226-39, 1987.
Brough et al., "A Gene Transfer Vector-Cell Line System for Complete Function Complementation of Adenovirus Early Regions E1 and E4," J. Virol., 70(9), 6497-6501 (1996).
Engelhardt et al., "Ablation of E2A in Recombinant Adenoviruses Improves Transgene Persistance and Decrease Inflammatory Response in Mouse Liver," Proc. Natl. Acad. Sci. USA, 91, 6196-6200 (1994).
Zhou et al., "Progress Towards Development of an Adenoviral Vector with Deletions of E1 and E2a," J. Cellular Biochemistry, (supp. 21A), 434 (1995).
Barr et al., Gene Therapy, 1, 51-58 (1994).
Berkner et al., Nucleic Acids Research, 11 (17), 6003-6020 (1983).
Boucher et al., Human Gene Therapy, 5, 615-639 (1994).
Brough et al. Virology, 196, 269-281 (1993).
Brough et al., Virology, 190, 624-634 (1992).
Crystal et al., Nature Genetics, 8, 42-51 (Sep. 1994).
Englehardt et al., Human Gene Therapy, 4, 759-769 (1993).
Fallaux et al., Human Gene Therapy, 7, 215-222 (1996).
Graham et al., J. Gen. Virol., 36, 59-72 (1977).
Klessig et al., Molecular and Cellular Biology, 4 (7), 1354-1362 (1984).
Kreeger, The Scientist, 13, (Feb. 19, 1996).
Krougliak et al., Humans Gene Therapy, 6, 1575-1586 (1995).
Lemarchand et al., PNAS USA, 89, 6482-6486 (Jul. 1992).
Lemarchand et al., [PNAS USA, 89, 6482-6486 (Jul. 1992).]
Mastrangeli et al., J. Clin. Invest., 91, 225-234 (Jan. 1993).
Rosenfeld et al., Cell, 68, 143-158 (1992).
Schaack et al., J. Virol., 69, 4079-4085 (1995).
Trapnell et al., Current Opinion in Biotechnology, 5, 617-625 (1994).
Vos et al., Virology, 172, 634-642 (1989).
Wang et al., Gene Therapy, 2, 775-783 (1995).
Weinberg et al., PNAS USA, 80, 5383-86 (1983).
Yang et al., PNAS USA, 91, 4407-4411 (1994).
Yeh et al., J. Virol., 70 (1), 559-565 (1996).

Affiliated with

Also associated with

Rating

Stocks of recombinant, replication-deficient adenovirus free of does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stocks of recombinant, replication-deficient adenovirus free of , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stocks of recombinant, replication-deficient adenovirus free of will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1670483